Aticaprant is a Small molecule drug targeting κ opioid receptor, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Tavapadon: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

Zanzalintinib is a Small molecule drug targeting AXL x MerTK x TYRO3 x VEGFR1 x c-Met, at NDA/BLA. This 2026 report reviews clinical evidence, IP, deals.

Atacicept-vymj is a Fc fusion protein targeting APRIL x BAFF, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Idecabtagene Vicleucel is a Autologous CAR-T targeting BCMA, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Zuranolone is a Small molecule drug targeting GABAA receptor, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Xanomeline Tartrate/Trospium Chloride: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

Fam-trastuzumab deruxtecan-NXKI: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

Lecanemab is a Monoclonal antibody targeting APP, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Patritumab Deruxtecan: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

Obicetrapib is a Small molecule drug targeting CETP, at NDA/BLA. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Vepdegestrant: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.